Immunome Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
The following table describes for the three months ended March 31, 2026 each trading arrangement under which the Company's officers, directors or director affiliated investment funds adopted, materially modified, or terminated any contracts, instructions, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
| Name and Position · Action · Adoption/TerminationDate · Rule 10b5-1(1) · Non-Rule10b5-1(2) · Total Shares ofCommon Stockto be Sold · ExpirationDate | |||||
|---|---|---|---|---|---|
| Robert Lechleider, Chief Medical Officer | Termination | March 26, 2026 | X | 110,000 | December 31, 2026 |
| Robert Lechleider, Chief Medical Officer | Adoption | March 26, 2026 | X | 110,000 | December 31, 2026 |
| Kinney Horn, Chief Business Officer | Adoption | March 30, 2026 | X | 132,853 | January 15, 2027 |
| Isaac Barchas, Director | Adoption | March 31, 2026 | X | 11,048 | March 15, 2027 |
| ABHMC II LLC, Investor (4) | Adoption | March 31, 2026 | X | 408,504 | December 31, 2027 |
| Arsenal Bridge Venture II-B LLC, Investor (5) | Adoption | March 31, 2026 | X | 1,050 | December 31, 2027 |
(1)
Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2)
"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(3)
Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on December 24, 2025 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(4)
The Rule 10b5-1 trading plan was adopted by ABHMC II LLC, or ABHMC. The shares held by ABHMC II LLC were received following an in-kind distribution of the Company's common stock from Arsenal Bridge Venture II, LLC, or ABV II, in accordance with its operating agreement. ABHMC is the managing member of ABV II. Mr. Barchas, a member of the Company's Board of Directors, is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABHMC. Mr. Barchas disclaims beneficial ownership of the shares covered by the Rule 10b5-1 trading plan, except to the extent of his pecuniary interest, if any.
(5)
The Rule 10b5-1 trading plan was adopted by Arsenal Bridge Venture II-B LLC, or ABV II-B. Mr. Barchas, a member of the Company's Board of Directors, is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II-B. Mr. Barchas disclaims beneficial ownership of the shares covered by the Rule 10b5-1 trading plan, except to the extent of his pecuniary interest, if any.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.